A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
Background and Objective: Parkinson is a common disease that caused by degeneration of nigrostriatal dopaminergic pathways. Drug therapy can prevent movement disorders in patients and so they can do independently their daily activities. Many drugs are used for treatment for this disease. This study...
Saved in:
Main Authors: | A Ahmadi Ahangar, SAR Sadraei Mousavi |
---|---|
Format: | article |
Language: | EN FA |
Published: |
Babol University of Medical Sciences
2002
|
Subjects: | |
Online Access: | https://doaj.org/article/e0dce7db8d0d468cbc7fe0c6d59d79af |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
by: Werner Poewe, et al.
Published: (2010) -
Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
by: Juri C,Carlos, et al.
Published: (2006) -
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
by: Daniel D Truong
Published: (2009) -
Síndrome neuroléptico maligno-like como complicación en enfermedad de Parkinson: Desenlace fatal. Reporte de un caso y revisión de la literatura
by: Salinas S,Carlos, et al.
Published: (2014) -
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
by: Via MA
Published: (2010)